Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Nov;80(5):1435–1445. doi: 10.1172/JCI113223

Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.

P Gresele 1, J Arnout 1, H Deckmyn 1, E Huybrechts 1, G Pieters 1, J Vermylen 1
PMCID: PMC442401  PMID: 2960694

Abstract

Thromboxane synthase inhibition can lead to two opposing effects: accumulation of proaggregatory cyclic endoperoxides and increased formation of antiaggregatory PGI2 and PGD2. The elimination of the effects of the cyclic endoperoxides by an endoperoxide-thromboxane A2 receptor antagonist should enhance the inhibition of hemostasis by thromboxane synthase blockers. We have carried out a series of double-blind, placebo-controlled, crossover studies in healthy volunteers to check if this hypothesis may be operative in vivo in man. In a first study, in 10 healthy male volunteers, the combined administration of the thromboxane receptor antagonist BM 13.177 and the thromboxane synthase inhibitor dazoxiben gave stronger inhibition of platelet aggregation and prolonged the bleeding time more than either drug alone. In a second study, in 10 different healthy male volunteers, complete inhibition of cyclooxygenase with indomethacin reduced the prolongation of the bleeding time by the combination BM 13.177 plus dazoxiben. In a third study, in five volunteers, selective cumulative inhibition of platelet TXA2 synthesis by low-dose aspirin inhibited platelet aggregation and prolonged the bleeding time less than the combination BM 13.177 plus dazoxiben. In vitro, in human platelet-rich plasma stimulated with arachidonic acid, the combination of BM 13.177 and dazoxiben increased intraplatelet cAMP while the single drugs did not affect it. Our results indicate that prostaglandin endoperoxides can partly substitute for the activity of TXA2 in vivo in man and that an increased formation of endogenous antiaggregatory and vasodilatory prostaglandins, as obtained with selective thromboxane synthase inhibitors, may contribute to the impairment of hemostasis.

Full text

PDF
1435

Images in this article

1440Image
on p.1440
1440Image
on p.1440
1440Image
on p.1440
1443Image
on p.1443

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BORN G. V., CROSS M. J. THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963 Aug;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartele V., Cerletti C., Schiepatti A., di Minno G., de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet. 1981 May 9;1(8228):1057–1058. doi: 10.1016/s0140-6736(81)92224-8. [DOI] [PubMed] [Google Scholar]
  3. Bertele V., De Gaetano G. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol. 1982 Dec 3;85(3-4):331–333. doi: 10.1016/0014-2999(82)90220-5. [DOI] [PubMed] [Google Scholar]
  4. Bonne C., Martin B., Watada M., Regnault F. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets. Thromb Res. 1981 Jan 1;21(1-2):13–22. doi: 10.1016/0049-3848(84)90028-8. [DOI] [PubMed] [Google Scholar]
  5. Brittain R. T., Boutal L., Carter M. C., Coleman R. A., Collington E. W., Geisow H. P., Hallett P., Hornby E. J., Humphrey P. P., Jack D. AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation. 1985 Dec;72(6):1208–1218. doi: 10.1161/01.cir.72.6.1208. [DOI] [PubMed] [Google Scholar]
  6. Cardinal D. C., Flower R. J. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980 Feb;3(2):135–158. doi: 10.1016/0160-5402(80)90024-8. [DOI] [PubMed] [Google Scholar]
  7. Catella F., Nowak J., Fitzgerald G. A. Measurement of renal and non-renal eicosanoid synthesis. Am J Med. 1986 Aug 25;81(2B):23–29. doi: 10.1016/0002-9343(86)90905-8. [DOI] [PubMed] [Google Scholar]
  8. Defreyn G., Deckmyn H., Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res. 1982 Jun 15;26(6):389–400. doi: 10.1016/0049-3848(82)90311-5. [DOI] [PubMed] [Google Scholar]
  9. Di Minno G., Silver M. J., Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood. 1983 Jun;61(6):1081–1085. [PubMed] [Google Scholar]
  10. FitzGerald G. A., Brash A. R., Oates J. A., Pedersen A. K. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest. 1983 Oct;72(4):1336–1343. doi: 10.1172/JCI111089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. FitzGerald G. A., Oates J. A., Hawiger J., Maas R. L., Roberts L. J., 2nd, Lawson J. A., Brash A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676–688. doi: 10.1172/JCI110814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. FitzGerald G. A., Pedersen A. K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983 Jun;67(6):1174–1177. doi: 10.1161/01.cir.67.6.1174. [DOI] [PubMed] [Google Scholar]
  13. FitzGerald G. A., Reilly I. A., Pedersen A. K. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation. 1985 Dec;72(6):1194–1201. doi: 10.1161/01.cir.72.6.1194. [DOI] [PubMed] [Google Scholar]
  14. Friedhoff L. T., Manning J., Funke P. T., Ivashkiv E., Tu J., Cooper W., Willard D. A. Quantitation of drug levels and platelet receptor blockade caused by a thromboxane antagonist. Clin Pharmacol Ther. 1986 Dec;40(6):634–642. doi: 10.1038/clpt.1986.238. [DOI] [PubMed] [Google Scholar]
  15. Gorman R. R., Fitzpatrick F. A., Miller O. V. Reciprocal regulation of human platelet cAMP levels by thromboxane A2 and prostacyclin. Adv Cyclic Nucleotide Res. 1978;9:597–609. [PubMed] [Google Scholar]
  16. Gresele P., Bounameaux H., Arnout J., Perez-Requejo J. L., Deckmyn H., Vermylen J. Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans. J Lab Clin Med. 1985 Nov;106(5):534–541. [PubMed] [Google Scholar]
  17. Gresele P., Deckmyn H., Arnout J., Lemmens J., Janssens W., Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet. 1984 May 5;1(8384):991–994. doi: 10.1016/s0140-6736(84)92328-6. [DOI] [PubMed] [Google Scholar]
  18. Gresele P., Deckmyn H., Arnout J., Vermylen J. Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer. Br J Haematol. 1984 May;57(1):171–173. [PubMed] [Google Scholar]
  19. Gresele P., Deckmyn H., Huybrechts E., Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol. 1984 Jul 1;33(13):2083–2088. doi: 10.1016/0006-2952(84)90577-x. [DOI] [PubMed] [Google Scholar]
  20. Gresele P., Van Houtte E., Arnout J., Deckmyn H., Vermylen J. Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy? Thromb Haemost. 1984 Dec 29;52(3):364–364. [PubMed] [Google Scholar]
  21. Gresele P., Zoja C., Deckmyn H., Arnout J., Vermylen J., Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost. 1983 Dec 30;50(4):852–856. [PubMed] [Google Scholar]
  22. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Harker L. A. Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation. 1986 Feb;73(2):206–223. doi: 10.1161/01.cir.73.2.206. [DOI] [PubMed] [Google Scholar]
  24. Haslam R. J., Davidson M. M., Davies T., Lynham J. A., McClenaghan M. D. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucleotide Res. 1978;9:533–552. [PubMed] [Google Scholar]
  25. Kattelman E. J., Venton D. L., Le Breton G. C. Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res. 1986 Feb 15;41(4):471–481. doi: 10.1016/0049-3848(86)91692-0. [DOI] [PubMed] [Google Scholar]
  26. Krishna G., Weiss B., Brodie B. B. A simple, sensitive method for the assay of adenyl cyclase. J Pharmacol Exp Ther. 1968 Oct;163(2):379–385. [PubMed] [Google Scholar]
  27. Levine L., Alam I., Langone J. J. The use of immobilized ligands and [125I]protein a for immunoassays of thromboxane B2, prostaglandin D2, 13,14-dihydro-prostaglandin E2, 5,6-dihydro-prostaglandin I2, 6-keto-prostaglandin F1 alpha, 15-hydroxy-9 alpha, 11 alpha(epoxymethano)prosta-5,13-dienoic acid and 15-hydroxy-11 alpha,9 alpha(epoxymethano)prosta-5,13-dienoic acid. Prostaglandins Med. 1979 Mar;2(3):177–189. doi: 10.1016/0161-4630(79)90035-1. [DOI] [PubMed] [Google Scholar]
  28. Marcus A. J., Weksler B. B., Jaffe E. A., Broekman M. J. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest. 1980 Nov;66(5):979–986. doi: 10.1172/JCI109967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Michel H., Caen J. P., Born G. V., Miller R., D'Auriac G. A., Meyer P. Relation between the inhibition of aggregation and the concentration of cAMP in human and rat platelets. Br J Haematol. 1976 May;33(1):27–38. doi: 10.1111/j.1365-2141.1976.tb00969.x. [DOI] [PubMed] [Google Scholar]
  30. Mills D. C., Macfarlane D. E. Stimulation of human platelet adenylate cyclase by prostaglandin D2. Thromb Res. 1974 Sep;5(3):401–412. doi: 10.1016/0049-3848(74)90176-5. [DOI] [PubMed] [Google Scholar]
  31. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366–1372. doi: 10.1172/JCI110576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 Feb 1;17(3-4):317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
  33. Rajtar G., Cerletti C., Castagnoli M. N., Bertelé V., de Gaetano G. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors. Biochem Pharmacol. 1985 Feb 1;34(3):307–310. doi: 10.1016/0006-2952(85)90036-x. [DOI] [PubMed] [Google Scholar]
  34. Riess H., Hiller E., Reinhardt B., Bräuning C. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. Thromb Res. 1984 Aug 15;35(4):371–378. doi: 10.1016/0049-3848(84)90229-9. [DOI] [PubMed] [Google Scholar]
  35. Schafer A. I., Crawford D. D., Gimbrone M. A., Jr Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest. 1984 Apr;73(4):1105–1112. doi: 10.1172/JCI111296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Smith J. B., Ingerman C., Silver M. J. Persistence of thromboxane A2-like material and platelet release-inducing activity in plasma. J Clin Invest. 1976 Nov;58(5):1119–1122. doi: 10.1172/JCI108564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Staiger C., Patscheke H., Neugebauer G., Kaufmann B., Strein K., Endele R., Stegmeier K. Single dose pharmacokinetics and effects on platelet function of the thromboxane receptor blocker BM 13.177. Eur J Clin Pharmacol. 1986;29(5):573–579. doi: 10.1007/BF00635895. [DOI] [PubMed] [Google Scholar]
  38. Tyler H. M., Saxton C. A., Parry M. J. Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet. 1981 Mar 21;1(8221):629–632. doi: 10.1016/s0140-6736(81)91551-8. [DOI] [PubMed] [Google Scholar]
  39. Vermylen J., Defreyn G., Carreras L. O., Machin S. J., Van Schaeren J., Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet. 1981 May 16;1(8229):1073–1075. doi: 10.1016/s0140-6736(81)92241-8. [DOI] [PubMed] [Google Scholar]
  40. Weksler B. B., Tack-Goldman K., Subramanian V. A., Gay W. A., Jr Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation. 1985 Feb;71(2):332–340. doi: 10.1161/01.cir.71.2.332. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES